ライフサイエンスコーパス: drug transporter

1 6, originally NKT), a major kidney-expressed drug transporter.

2 of Sav1866, a bacterial ATP-binding cassette drug transporter.

3 est in mice proficient and deficient of mdr1 drug transporters.

4 ble structural data for this family of multi-drug transporters.

5 ZD2461 was developed as a poor substrate for drug transporters.

6 of OATP1B1, MRP2, MDR1, and other important drug transporters.

7 believed to belong to the category of single-drug transporters.

8 some of which are handled by DMEs, including drug transporters.

9 l role controlling these two important renal drug transporters.

10 other EGFR TKI, erlotinib, with selected ABC drug transporters.

11 pread phosphotyrosine-mediated regulation of drug transporters.

12 volume address the structure and function of drug transporters.

13 sult of overexpression of the P-glycoprotein drug transporter, a product of the MDR1 gene, is a signi

14 Sulfite oxidase (SUOX) expression and the drug-transporter ABCC1 (MRP1) were linked to thiopurine

15 ildenafil affect the function of another ABC drug transporter, ABCC1.

16 The role of the ATP-dependent drug transporter ABCG2 in CPT-11 cytotoxicity is unclear

17 n of adenosine triphosphate-binding cassette drug transporter ABCG2 in DLBCL correlated inversely wit

18 Cell line studies have suggested that the drug transporter ABCG2 may be a mediator of IM resistanc

19 n of the breast cancer resistance-associated drug transporter (ABCG2), reversing resistance to campto

20 Consequently, the oligomers suppress drug transporter activity and increase sensitivity to do

21 on is not directly involved in regulation of drug transporter activity.

22 that P-glycoprotein, an ATP-dependent efflux drug transporter and an integrated component of the occl

23 Our results identify ABCB5 as a novel drug transporter and chemoresistance mediator in human m

24 oma cell line known to overexpress the ABCB1 drug transporter and was also unaffected by overexpressi

25 a parasites have been identified in putative drug transporters and in target enzymes.

26 cell surface receptors, cytokeratin markers, drug transporters and the efficient efflux of the Hoechs

27 Recent work has investigated drug transporters and the variants of genes encoding dru

28 hosphorylation-dependent interaction between drug transporters and tyrosine kinase inhibitors (TKIs),

29 ing resistance associated with expression of drug transporters and/or antiapoptotic proteins.

30 chrome P450s, glutathione S-transferases and drug transporters, and investigated the regulation of ge

31 ded cytokine-cytokine receptor interactions, drug transporters, and mitogen-activated protein kinase,

32 CD44, the EGF receptor, the ABCB1 and ABCG2 drug transporters, and the MCT4 monocarboxylate transpor

33 Drug transporters are an important part of the defense o

34 Along with OCT2, other SLC-family drug transporters are potentially part of an extensive '

35 g CYP3A, and multiple intestinal and hepatic drug transporters are thought to mediate this process, b

36 rrent understanding of the regulation of ABC drug transporters at the level of transcription.

37 tein showed 87% homology with the bacitracin drug transporter BcrA of Staphylococcus hominis.

38 l as unfavorable drug disposition exerted by drug transporters before the drug reach retina.

39 Drug transporters can be specific to a particular drug,

40 ts, discovered in recent years, that inhibit drug transporters can potentially be used to overcome ef

41 he pulling velocity in force distance cycles drug-transporter complexes were ruptured at different fo

42 We determined that nine potential drug transporters contribute to drug resistance of Salmo

43 Drug transporters could play a significant role in the e

44 l sorting analysis suggests that these three drug transporters do little to reduce the cellular accum

45 ilability through PXR-mediated regulation of drug transporters (e.g., by other drugs) has the potenti

46 to Bac8c (including biofilm formation, multi-drug transporters, etc).

47 ification of MRP1, another member of the ABC drug transporter family, led to the realization that the

48 ll goal is to facilitate an understanding of drug transporters for PrEP optimization.

49 lyzed here transcriptional regulation of the drug transporter gene PDR5 in a drug-resistant pdr1-3 st

50 primary transcription activator of multiple drug transporter genes in S. cerevisiae, including PDR5.

51 resistance as a result of overexpression of drug transporter genes presents a major obstacle in the

52 underlying transcriptional up-regulation of drug transporter genes remains elusive.

53 romyces cerevisiae, transcription of several drug transporter genes, including the major transporter

54 -ATP binding and hydrolysis to function as a drug transporter; however, the mechanism(s) defining the

55 The drug transporter hypothesis for refractory epilepsy prop

56 In summary, the expression of drug transporters (i) is markedly changed in HNSCC tumor

57 tic insights into the role of OAT1 and other drug transporters implicated in metabolic diseases like

58 cassette (ABC) transporter LmrA is a primary drug transporter in Lactococcus lactis that can function

59 rganic cation transporter-3), a polyspecific drug transporter in the solute carrier 22 family.

60 are compatible with the hypothesized role of drug transporters in remote inter-organ and inter-organi

61 In conclusion, modulation of drug transporters in sandwich-cultured rat hepatocytes b

62 gh examination of the expression of the main drug transporters in the kidney throughout all stages of

63 uld modify the expression and/or activity of drug transporters in the liver.

64 mining the evolutionary relationship between drug transporters in zebrafish and humans.

65 olutes and supports the centrality of these "drug" transporters in independently and synergistically

66 9 standard anticancer drugs identified known drug-transporter interactions and suggested novel ones.

67 To examine drug-transporter interactions at the molecular level, we

68 to be a substrate of human P-glycoprotein, a drug-transporter involved in all steps of pharmacokineti

69 verexpression of the gene encoding the ABCC3 drug transporter is responsible for conferring in vitro

70 considered beyond simple competition for the drug transporter itself and may explain aspects of drug-

71 e hyaluronan-CD44 interactions contribute to drug transporter localization and function at the plasma

72 nd ATP binding cassette (ABC) multispecific "drug" transporters maintain effective organ and body flu

73 Although the functions of drug transporters may involve both the protection of bac

74 remic toxins, such as IS, through effects on drug transporters, may modify the nonrenal clearance of

75 ase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.

76 questered into the Golgi apparatus through a drug transporter-mediated process.

77 was not detected in cells overexpressing the drug transporters MRP1 or MXR.

78 ions of glutathione S-transferase P1 and the drug transporter multidrug resistance associated protein

79 together, our data provide evidence that the drug transporter OATP1B3 functions as a determinant of t

80 kynurenine, creatinine, urate) include two "drug" transporters of the organic anion transporter (OAT

81 r physiological importance of multispecific "drug" transporters of the SLC and ABC transporter famili

82 Herein we show that among this class of drug transporters, only ABCG2 was expressed at highly in

83 expression of the ATP-binding cassette (ABC) drug transporter P-glycoprotein (P-gp) is often responsi

84 Localization of the drug transporter P-glycoprotein (Pgp) to the plasma memb

85 notably cytochrome p450 isozymes) and/or the drug transporter P-glycoprotein include garlic (Allium s

86 tory reaction and maintained assembly of the drug transporter p-gp.

87 O refractory patients frequently express the drug transporters P-glycoprotein (Pgp) and/or multidrug

88 any detectable expression of the three major drug transporters P-glycoprotien, multidrug resistance-a

89 hepatic enzyme, cytochrome P450 3A, and the drug transporter, P-glycoprotein, which predisposes thes

90 n of several key cytochrome P450 enzymes and drug transporter proteins in liver and intestine in a sp

91 battery of genes encoding cytoprotective and drug transporter proteins in response to chemical and ra

92 High expression of antiapoptotic and/or drug transporter proteins induced by oncogenic signaling

93 ation of DOX and decreases the expression of drug transporter proteins MDR1, MRP1, and ABCG2.

94 st 33342 is mediated by ATP binding cassette drug transporter proteins that also contribute to chemor

95 ss high levels of ATP-binding cassette (ABC) drug transporters, providing for a level of resistance;

96 This study identifies numerous potential drug-transporter relationships and supports a prominent

97 tein SACOL2566 (5.2-fold), and the BcrA-like drug transporter SACOL2525 (5.7-fold) genes.

98 tion and expression of both major classes of drug transporters, SLC and ABC, in resting human blood n

99 Additional drug transporters, such as the multidrug resistance-asso

100 angement that regulates expression of an ABC drug transporter, suggesting a new target for circumvent

101 ABCG2 is a half-ATP binding cassette (ABC) drug transporter that consists of a nucleotide binding d

102 ting polypeptide OATP1B3 is a membrane-bound drug transporter that facilitates cellular entry of a va

103 ic drugs by inducing expression of the ABCB1 drug transporter that prevents intracellular drug accumu

104 genes encoding drug-metabolizing enzymes and drug transporters to essentially detoxify and eliminate

105 of the ATP-binding cassette (ABC) family of drug transporters, was first identified almost three dec

106 None of the known T. b. brucei drug transporters were required for trypanocidal activit

107 e MDR1 gene product P-glycoprotein (P-gp), a drug transporter which severely impedes the efficacy of

108 (WHITE), member 2 (ABCG2), an anthracycline drug transporter, which lead to significantly increased